These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7512128)

  • 41. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
    Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
    J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
    Petrelli N; Herrera L; Rustum Y; Burke P; Creaven P; Stulc J; Emrich LJ; Mittelman A
    J Clin Oncol; 1987 Oct; 5(10):1559-65. PubMed ID: 2443619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics.
    Hines JD; Adelstein DJ; Spiess JL; Giroski P; Carter SG
    Cancer; 1989 Mar; 63(6 Suppl):1022-5. PubMed ID: 2783879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer.
    Romero AO; Perez JE; Cuevas MA; Lacava JA; Sabatini CL; Dominguez ME; Rodriguez R; Barbieri MR; Ortiz EH; Salvadori MA; Acuña LA; Acuña JM; Langhi MJ; Amato S; Machiavelli MR; Leone BA; Vallejo CT; Lorusso V; DeLena M
    Am J Clin Oncol; 1998 Feb; 21(1):94-8. PubMed ID: 9499269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer.
    Stabuc B; Markovic A; Plesnicar A; Cizej TE
    Neoplasma; 2000; 47(4):248-52. PubMed ID: 11043831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer.
    Marsh JC; Bertino JR; Katz KH; Davis CA; Durivage HJ; Rome LS; Richards F; Capizzi RL; Farber LR; Pasquale DN
    J Clin Oncol; 1991 Mar; 9(3):371-80. PubMed ID: 1999706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer.
    Matsumura Y; Haruyama K; Hamaguchi T; Shirao K; Muro K; Yamada Y; Shimada Y; Sugano K
    Jpn J Clin Oncol; 2002 Jan; 32(1):9-13. PubMed ID: 11932356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.
    Amado RG; Rosen LS; Hecht JR; Lin LS; Rosen PJ
    Ann Oncol; 2002 Apr; 13(4):582-8. PubMed ID: 12056709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
    Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
    J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
    Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
    Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
    J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.
    Tsavaris N; Kosmas C; Gennatas K; Vadiaka M; Paliaros P; Dimitrakopoulos A; Diamantis T; Tsipras H; Papastratis G
    Med Sci Monit; 2002 Sep; 8(9):PI65-9. PubMed ID: 12218954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
    Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
    Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Early phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group].
    Sugano K; Ota K; Taguchi T; Ogawa N; Kurihara M; Akazawa S; Ogawa M; Tominaga T; Sasaki T; Konishi T
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):627-37. PubMed ID: 7717714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
    Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells.
    Falcone A; Lencioni M; Brunetti I; Pfanner E; Allegrini G; Antonuzzo A; Andreuccetti M; Malvaldi G; Danesi R; Del Tacca M; Conte PF
    Ann Oncol; 1997 Jun; 8(6):539-45. PubMed ID: 9261522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.